Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "CRDMO"

43 News Found

Jubilant Biosys appoints Venugopala Reddy Pagadala as VP&CFO - CRDMO
People | July 28, 2025

Jubilant Biosys appoints Venugopala Reddy Pagadala as VP&CFO - CRDMO

His career spans notable tenures at Syngene International Limited, Cipla, Nestlé, and Bharat Petroleum Corporation Limited


India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report
News | February 26, 2025

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain


WuXi Biologics breaks ground on CRDMO Center in Singapore
News | March 28, 2024

WuXi Biologics breaks ground on CRDMO Center in Singapore

The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network


Sai Life Sciences to double process R&D capacity with new facility in Hyderabad
R&D | October 28, 2025

Sai Life Sciences to double process R&D capacity with new facility in Hyderabad

The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization


Syngene International expands capabilities with new bioconjugation suite in Bengaluru
News | October 25, 2025

Syngene International expands capabilities with new bioconjugation suite in Bengaluru

Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services


Aragen appoints Neeraj Garg as CEO - Discovery Solutions business
People | October 16, 2025

Aragen appoints Neeraj Garg as CEO - Discovery Solutions business

In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base


Syngene International invests in peptide laboratory in Bengaluru
News | October 16, 2025

Syngene International invests in peptide laboratory in Bengaluru

Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services


Sai Life Sciences completes Phase II of production block 11 at Bidar
News | August 29, 2025

Sai Life Sciences completes Phase II of production block 11 at Bidar

With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL


Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr
News | August 17, 2025

Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr

The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase